After 108 weeks, changes in UACR from baseline with lixisenatide were 1.69% [(95% CI: 11.69 to 8.30), p=0.7398] in patients with normoalbuminuria, 21.10% [(95% CI: 42.25 to 0.04), p=0.0502] in patients with microalbuminuria, and 39.18% [(95% CI: 6853 to 984), p=0.0070] in patients with macroalbuminuria
Quick Answer: Semaglutide produces modest reductions in total cholesterol, LDL cholesterol, and triglycerides as a secondary benefit, primarily through weight loss rather than direct lipid-lowering action
Try IV Therapy IV therapy can help reduce bloating by replenishing your body with fluids, nutrients, and more
Testimonials Kind Words from Our Patients Discover the stories of lives transformed and experiences shared by our valued patients
Following the phase 2 results published in 2023, Eli Lilly has progressed retatrutide into phase 3 clinical development
This is the main reason that lower-quality intravenous glutathione injections are now being popularized by IV parlors and Spas offering IV therapy for just about any condition